Get the full Irritable Bowel Syndrome Treatment market evidence
The purchased report supplies researched market size, forecast, growth, segments, competition and sources.
Australia
Brazil
Canada
China
Ecuador
Egypt
France
Germany
Hong Kong
India
Italy
Japan
Kenya
Malaysia
Mexico
New Zealand
Philippines
Russia
Saudi Arabia
Singapore
South Africa
Spain
Thailand
UAE
UK
USPublic clinical research
185 active trials found worldwide on ClinicalTrials.gov.
See the public searchLatest public research
- Heterogeneity and patient stratification in fibromyalgia and irritable bowel syndrome treatment studies: systematic review discussion.Clinical rheumatology, 2026
- Microalgae-based Intestinal villi-targeting multistage biosystem for irritable bowel syndrome treatment.Nature communications, 2025
- Mechanistic Insights Into Prucalopride's Role in Irritable Bowel Syndrome Treatment: Schwann-like Enteric Glial Cells as Therapeutic Targets.Gastroenterology, 2025
- Constipation-predominant irritable bowel syndrome treatment options Linaclotide, Lubiprostone, Plecanatide, and Tenapanor: analysis of the FDA Adverse Event Reporting System (FAERS) database.Expert opinion on drug safety, 2025
- Diarrhea-predominant irritable bowel syndrome treatment options eluxadoline, rifaximin, and alosetron: analysis of the FDA adverse event reporting system (FAERS) database.Expert opinion on drug safety, 2025
Public trial and paper counts come from ClinicalTrials.gov and PubMed. Acuitas market figures are not published on this page.